30 closest matches · ranked by relevance
Gastrointestinal Cancer
Primary: Feasibility: Number and Percentage of Participants Who Had Their Pharmacogenetic Tests Returned Prior to Initial Dose — 130; 95 Participants
Adverse Drug Events · Adverse Drug Reactions · Drug Interaction Potentiation
Primary: Number of Re-hospitalizations at 30 and 60 Days — 0.38; 0.25; 0.7; 0.33 Re-hospitalizations — p=0.21
Cardiovascular Disease
Primary: 12-Month Change in LDL Cholesterol — -1.1; -2.2 mg/dL
Pharmacogenetic Testing
Primary: Clinical Global Impression — 4.07; 3.96 units on a scale — p=<0.05
Pharmacogenetics
Primary: Number of Patient Participants' Acceptance of PGx Services Offered in Community Pharmacy Setting — 14; 13 Participants
Gastroesophageal Reflux
Primary: Count of Patients Agreeing to Volunteer for the Study — 28 Participants
Acute Pain · Post Operative Pain
Primary: Feasibility of Integrating a PGx Panel Test in the EMR With a Pharmacist Consult Note for Each Patient — 35; 0 Participants
Cancer · Depression · Pain
Primary: Proportion of Participants Receiving at Least One Drug/Dose Selection or Modification Based on PGx Results — 9 Participants
Antidepressants Causing Adverse Effects in Therapeutic Use
Primary: Count of Participants Prescribed Antidepressant Medication — 5; 8; 5; 8 Participants
Venous Thromboembolism · Bleeding
Primary: The Number of Participants With Adverse Events Associated With Warfarin Anticoagulation Following Total Hip and Total Knee Replacement — 2; 4 participants
Depression
Primary: Percentage Change in Quick Inventory of Depressive Symptomatology (QIDS-C16) Score From Baseline — -41.2; -11.0; -48.4; -31.8 Percentage change in depression rating…
Metabolism of Clopidogrel
Primary: Change in Platelet Aggregation Following Therapy With Clopidogrel — 62.9; 68.1; 62.5; 63.2 percentage of aggregation
Blood Coagulation Disorders
Primary: Inpatient Length of Stay — 6.8; 7.2 days
Depression · Anxiety
Primary: Number of Outpatient Visits — 13 units on a scale
Pharmacogenetic Testing
Primary: Change in Global Patient Treatment Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) — 59.9; 64.4 score on a scale — p=0.001
Thromboembolism
Primary: The Percent of Out of Range (OOR) International Normalized Prothrombin Time Ratio (INRs) in the Standard and Modified Pharmacogenetic Arms. — 30.6; 31.8 percent — p=<0.05
Pain · Other Surgical Procedures · Impacted Third Molar Tooth
Primary: Score of Pain Measured by Visual Analogue Scale — 25 score on a scale (mm)
Platelet Aggregation · Platelet Transcriptome · Coronary Artery Disease
Primary: Difference in ADP-induced Platelet Aggregation — -5.2 Difference in ohms (Post-Pre)
Asthma
Primary: Log10 PC20 to Methacholine After Visit 2 — 0.54; 0.48; 0.16; 0.53 log10 mg/mL — p=0.27
Coronary Artery Disease · Acute Coronary Syndrome · Stenosis
Primary: Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. — 35; 54 Participants
Chronic Kidney Disease · Hypertension
Primary: Change in Systolic Blood Pressure From Baseline to 3 Months for APOL1 Negative Participants — -3.7; -3.1 mmHg — p=0.4852
Congenital Bleeding Disorder · Haemophilia A With Inhibitors · Haemophilia B With Inhibitors
Primary: Determination of HLA Type — 15; 5; 5; 1 subjects
Postoperative Nausea
Primary: Episodes of Postoperative Nausea — 0; 16 episodes
Type 2 Diabetes
Primary: Change in Insulin Resistance — -0.83 HOMA-IR index is unitless by definition — p=<0.0000001
Kidney Transplantation
Primary: Tacrolimus Bioavailability (F) — 0.224; 0.681 ratio of oral to IV — p=0.006
Healthy
Primary: Warfarin Clearance. — 282; 246; 180; 84 mL/h — p=<0.0001
Major Depression
Primary: Depression Remission — 130; 126 Participants
Hypertension
Primary: Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)). — -12.06; -13.33 mmHg
Hypercholesterolemia · Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Primary: Morisky Medication Adherence Scale (MMAS) Score — 6.8; 6.9; 6.8; 7.1 units on a scale — p=0.96
Acute Coronary Syndrome · Cardiovascular Diseases
Primary: The Number (Percentage) of Participants Receiving Prasugrel/Ticagrelor — 174; 201; 75; 54 Participants — p=0.03